BioSpace News Archive

Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added to baseline immunosuppressant therapy.

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization, announced it is partnering with AdaptVac to develop and produce a COVID-19 vaccine.

Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to divest a portfolio of select non-core over-the-counter and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland to Orifarm Group, a fast-growing Danish pharmaceutical company, for up to approximately $670 million USD subject to customary legal and regulatory closing conditions.

BIO KOREA 2020 International Convention, where global bio experts correspond, is shifting to an online-only event.

Mesoblast Limited announced 83% survival in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome treated during the period March-April 2020 with two intravenous infusions of Mesoblast’s allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days.

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced that the European Investment Bank has approved a €50 million non-dilutive financing for the Company.

During these uncertain times, citizens have been searching for peace of mind. Normalcy has been found in COVID-19 antibody testing. Doctors and researchers are discovering that many Americans who have recovered from COVID-19 have the antibodies that could save others currently at risk or battling the virus.

Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), an online provider of healthcare information, professional training and educational services to healthcare professionals and the public in China, announced today the launch of virtual seminar series (

Cambium Networks Corporation (“Cambium Networks”) (NASDAQ: CMBM), a leading provider of wireless networking infrastructure solutions, today announced that it plans to report financial results for the first quarter 2020 ended March 31, 2020 on Tuesday, May 12, 2020.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2020. The call will be led by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus senior leadership team. Interested participants and investors may a